Press Releases Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Real-time Estimate Cboe BZX Other stock markets 12:50:36 2024-05-07 pm EDT			5-day change	1st Jan Change
7.755 ^USD	+2.44%		+18.15%	+30.61%

02:26pm	Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 27	North American Morning Briefing : Stock Futures -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cogent Biosciences Reports First Quarter 2024 Financial Results	08:02am	AQ
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)	Apr. 18	PR
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor	Apr. 09	AQ
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	Feb. 26	AQ
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	Feb. 22	AQ
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement	Feb. 14	AQ
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting	Feb. 05	AQ
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics	Jan. 09	AQ
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	AQ
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)	Dec. 11	AQ
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)	Dec. 09	AQ
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium	Dec. 07	AQ
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting	Dec. 04	AQ
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium	Nov. 29	AQ
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results	Nov. 02	AQ
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-14	AQ
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results	23-08-08	AQ
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock	23-06-09	AQ
COGENT BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-06-08	AQ
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference	23-06-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Press Releases

Filters